Products

AstraZeneca
AstraZeneca
Drug Discovery & Research
MILTON is an AI-powered platform by AstraZeneca focused on accelerating drug discovery and development through advanced data analysis.

See all 1 product →

About AstraZeneca

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company that focuses on the discovery, development, and commercialization of prescription medicines. The company’s portfolio addresses major diseases in areas such as oncology, rare diseases, and biopharmaceuticals, which include cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca operates globally, with a significant commercial presence in the United States, Europe, China, and other emerging markets.

AstraZeneca is actively leveraging artificial intelligence (AI) across its operations, from drug discovery and development to clinical trials and commercialization. The company has an Enterprise AI Unit that integrates scientific knowledge with advanced AI and data capabilities to accelerate the delivery of new medicines. For instance, AI is used to identify promising drug targets, optimize clinical trial design and patient selection, and even generate personalized insights for healthcare provider and patient combinations. AstraZeneca’s AI clinical trials technology is being deployed at a national healthcare system scale, demonstrating its impact beyond internal R&D pipelines.

Focus Areas

oncology cardiovascular renal & metabolism respiratory & immunology rare disease neuroscience infection gastrointestinal inflammation biologics vaccines

Business Intelligence

Key InvestorsPublicly traded, broadly held institutional ownership with no controlling shareholder publicly disclosed.
PartnershipsAWS, University of Oxford, TransCelerate BioPharma Inc., Verge Genomics, SOPHiA GENETICS, AI Sweden, KTH Royal Institute of Technology, Federation of European Academies of Medicine (FEAM), University of Manchester Institute of Cancer Sciences, Centre for Cancer Biomarker Sciences, Christie National Health Service Foundation Trust, Stanford Medicine, Cancer Research Horizons, ServiceNow, Laiye, National Health Service (NHS) Scotland, Daiichi Sankyo
AcquisitionsAlexion Pharmaceuticals (2021), MedImmune (2007), Cambridge Antibody Technology (2006), KuDOS Pharmaceuticals (2005), Spirogen (2013), Definiens (by MedImmune in 2014), TeneoTwo (2022), LogicBio Therapeutics (2022), Neogene Therapeutics (2022), Amolyt Pharma (2024), Fusion Pharmaceuticals Inc (2024), Gracell Biotechnologies (2024), Icosavax (2024), CinCor Pharma (2023), EsoBiotec (2025), Modella (2026), Proliferon Inc (2000), Enobia Pharma Corp (2011), Synageva BioPharma (2015), Wilson Therapeutics (2018), Syntimmune (2018), Achillion Pharmaceuticals (2019), Portola Pharmaceuticals (2020), Caelum Biosciences (2021), Almirall (2014), Pearl Therapeutics (2013), Ardea Biosciences (2012)
TechnologyAI-driven automation, machine learning, deep learning, natural language processing, cloud-native (with AWS), digital twins, AI operating system (AZ Brain commercial platform), Biological Insights Knowledge Graph, MILTON (MachIne Learning with phenoType associatiONs), Watcher (AI-based decision support system), ENaBL (Engineered NanoBody Lentiviral) platform
FDA Clearancesunknown cleared products (estimated)

What Physicians Need to Know

Oncology
AstraZeneca aims to revolutionize cancer care with a bold ambition to eliminate cancer as a cause of death. They focus on key tumor areas including lung, breast, gastrointestinal, gynecological, genitourinary, and hematology cancers. Their approach involves personalized treatments, targeted therapies, immuno-oncology, DNA Damage Response (DDR), antibody-drug conjugates (ADCs), radioconjugates (RCs), cell therapy, immune cell engagers, and epigenetics. They are recognized for their innovation in targeted therapy and ADC therapy.
Cardiovascular, Renal & Metabolism (CVRM)
AstraZeneca is dedicated to transforming the treatment of CVRM diseases, aiming to stop and reverse these conditions. They focus on cardiology, nephrology, type 2 diabetes, heart failure, and cardiorenal syndrome. Their strategy involves understanding the interconnections of these diseases and investing in innovative small molecules, drug combinations, nucleotide-based treatments, and advanced biologics. They are also exploring precision medicine approaches for conditions like amyloid transthyretin amyloidosis.
Respiratory & Immunology
With over 40 years of experience, AstraZeneca is a leader in respiratory care and aims to be a disruptor in immunology. Their ambition is to move beyond symptom control to disease modification, remission, and potentially cure for conditions like asthma, COPD, and lupus. They are developing innovative treatments to reduce the frequency and severity of asthma attacks and improve lung function in COPD. Their immunology focus includes rheumatology (e.g., lupus), dermatology, gastroenterology diseases, and systemic eosinophilic-driven diseases.
Rare Disease
AstraZeneca, through Alexion, AstraZeneca Rare Disease, is a pioneer in rare diseases, focusing on discovering, developing, and delivering life-changing medicines for devastating conditions. They embrace uncertainty in exploring disease states where scientific progress has stalled and unmet needs are high. Their pipeline spans multiple therapeutic areas, including hematology, nephrology, neurology, bone metabolism, cardiology, endocrinology, and rare cancers. They are advancing genomic medicine, advanced diagnostics, and novel therapies, including those targeting the complement system and genetic causes of diseases.
Neuroscience
While AstraZeneca has historically had a neuroscience research group, they have strategically shifted to focus resources on core therapeutic areas and 'high value' projects, discontinuing programs for Alzheimer's, migraine, and pain. They are selectively active in neuroscience, often through partnerships, with a focus on neurodegenerative diseases, analgesia, and psychiatry.
Infection & Vaccines
AstraZeneca has a longstanding heritage in developing vaccines and antibody therapies to reduce the global health burden of viral and bacterial infectious diseases. They are building an innovative portfolio of transformative products, including next-generation vaccines (e.g., self-amplifying RNA, mRNA, virus-like particles) and long-acting antibodies. Their focus areas include preventing viral respiratory diseases (influenza, RSV, hMPV, COVID-19), serious bacterial infections, and advancing therapies for persistent viral infections.
Physician Tip

AstraZeneca emphasizes a science-led approach, focusing on breakthrough science to discover disease mechanisms and develop novel, targeted therapies. They are committed to personalized healthcare, helping physicians identify patients eligible for appropriate treatment options by understanding disease biology and utilizing biomarkers and companion diagnostics. They actively partner and collaborate with physicians and institutions for education and research, believing that well-informed physicians lead to better patient outcomes and reduced costs. Physicians can expect access to advanced tools, technologies, and facilities, and opportunities to engage in world-class medical research with a focus on ethical standards and work-life balance.

AstraZeneca aggressively integrates artificial intelligence (AI) into drug discovery and development, with over 90% of small molecule discovery being AI-assisted. They leverage AI across the entire value chain, from target identification to clinical trial design and operational planning. Their technology stack includes Salesforce Agentforce Life Sciences for CRM, Tempus, Pathos, Databricks, and Tableau for data and analytics, and Adobe for marketing and creative operations. They utilize cloud platforms like AWS and Azure, including Azure OpenAI and Azure AI Foundry, for their AI stack. They are also pioneering 'Agentic Modelling and Simulation' using platforms like Quau00edsr and leveraging digital twins to accelerate pharmaceutical manufacturing.

Products by AstraZeneca

1 product in the directory

AstraZeneca
AstraZeneca
Drug Discovery & Research
MILTON is an AI-powered platform by AstraZeneca focused on accelerating drug discovery and development through advanced data analysis.

What the Web Says

AstraZeneca receives mixed reviews as an employer, with many highlighting good pay and benefits, work-life balance, and a positive culture in some departments. However, common criticisms include a lack of promotion opportunities, high work pressure, and issues with management and internal restructuring. Product quality is generally rated well by users, particularly in the accounting industry.

Overall: Mixed

Strengths

  • Good pay and benefits
  • Good work-life balance in many roles
  • Supportive colleagues and management in some teams
  • Emphasis on science and R&D in some departments
  • Opportunities for learning and development
  • Strong focus on sustainability and ecology

Limitations

  • Lack of promotion opportunities and slow career progression
  • High work pressure and demanding expectations
  • Inconsistent management quality and leadership issues
  • Frequent restructuring and layoffs
  • Cut-throat and competitive culture in some areas
  • Workload piling onto existing staff due to unfilled positions

Based on reviews from: Indeed.com, Reddit (r/biotech), Comparably, Drugwatch.com, Quora, Patsnap Synapse

Last updated: 2026-10-12

Videos

News, demos, and interviews about AstraZeneca.

Loading videos...

Videos load interactively. If none appear, search YouTube for AstraZeneca →

View all on YouTube

Press & Coverage

AstraZeneca Press Release
AstraZeneca completes equity investment in Summit Therapeutics
AstraZeneca has completed a $2 billion equity investment in Summit Therapeutics to accelerate the development of ivonescimab, a bispecific antibody for cancer treatment. This investment also includes a clinical collaboration to evaluate ivonescimab in combination with other AstraZeneca cancer medicines.
2026-10
AstraZeneca Press Release
AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts
AstraZeneca has opened a new $1 billion, 570,000 sq ft R&D center in Kendall Square, Cambridge, Massachusetts, integrating AI and robotics to accelerate drug discovery and development. This investment supports AstraZeneca's goal of reaching $80 billion in revenue by 2030, with 50% from its US operations.
2026-10
AstraZeneca Press Release
AstraZeneca and Daiichi Sankyo announce clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumour types
AstraZeneca and Daiichi Sankyo have announced a clinical collaboration with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) in combination with ivonescimab for various tumor types, starting with a Phase 3 trial for triple-negative breast cancer.
2026-10
Fierce Pharma
AstraZeneca recommits to youth health to dial funding past $100M
AstraZeneca has renewed its commitment to the UNICEF-partnered Young Health Programme (YHP) with a new five-year phase, bringing the total investment in the initiative to over $100 million by 2030. The program aims to reach an additional 10 million young people and train 800,000 youth advocates.
2026-09
AstraZeneca US Media
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
BREZTRI has received US approval as the first and only fixed-dose triple therapy for asthma patients aged 12 and older. This approval provides a new treatment option for a significant patient population.
2026-09
Endpoints News
AstraZeneca looks to AI to ease risk in late-stage trials, speed up filings
AstraZeneca is leveraging AI to improve the success rate of late-stage drug trials and accelerate regulatory filings, though AI-designed candidates are still in preclinical stages. The company is investing in partnerships to develop tools that predict trial success and optimize protocols.
2026-07
Human Vaccines & Immunotherapeutics
Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study
A retrospective cohort study found that two doses of the AstraZeneca (ChAdOx1-S) vaccine significantly reduced in-hospital mortality by 55% in individuals with COVID-19 and schizophrenia. One dose did not show a significant reduction in mortality.
2024-07
pharmaphorum
AstraZeneca reportedly hit by serious cyberattack
A hacking group known as LAPSUS$ claims to have breached AstraZeneca's IT systems and stolen approximately 3GB of confidential data, which they are attempting to sell on the Dark Web.
2026-03
No FAQs available yet for this company.

Related Companies

Google DeepMind is a leading artificial intelligence (AI) research laboratory, a subsidiary of Alphabet Inc., dedicated to developing advanced AI systems to benefit humanity. The company focuses on creating general-purpose AI that can learn and solve complex problems, drawing inspiration from neuroscience and machine learning. Their work spans various fields, including healthcare, scientific discovery, and […]

TalkToMedi is a Canadian healthcare AI company that has developed a clinical-grade voice AI platform called MEDI. This platform is designed to automate patient communication and administrative tasks for medical clinics, including family medicine, specialty clinics, allied health, and physiotherapy. MEDI handles high-volume patient calls, automating appointment inquiries, booking, rescheduling, and cancellations based on the […]

Menaela is an AI-first practice management system designed for solo practitioners, small private clinics, and clinic owners. It integrates patient communication, scheduling, CRM, and medical documentation into a single platform, aiming to replace multiple disconnected tools and bots. The system features an AI practice manager that understands natural-language requests, utilizes real clinic data, and performs […]

Avie (avie.me) is a healthcare AI company that focuses on providing a next-generation, whole-person health approach, bridging the gap between clinical and holistic care. The company connects individuals with providers and clinicians who can support their unique physical, emotional, cognitive, and logistical needs. Avie emphasizes fusing physical and mental best practices to enhance overall health, […]

Saile is a physician-founded healthcare technology company that addresses critical inefficiencies in healthcare staffing and credentialing. Their AI-powered platform acts as a “universal credential passport” for physicians, centralizing and managing all medical licenses, certifications, and CME credits in one secure, portable vault. This system aims to significantly reduce the administrative burden and delays associated with […]

Data Capture Experts (DCE) is an Australian-based healthcare AI company that is at the forefront of digital health transformation. They specialize in developing and implementing digital health platforms that integrate data, technology, and human-centered design to create intuitive and connected healthcare systems. Their flagship platform, DC2Vue, is designed to go beyond traditional Electronic Medical Records […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.